NasdaqGS:MDGLBiotechs
Rezdiffra Sales Milestone and Pfizer DGAT-2 Deal Might Change The Case For Investing In Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals recently reported that its liver disease drug Rezdiffra has reached over US$1.00 billion in annualized sales, while also signing an exclusive global license agreement with Pfizer for ervogastat, a clinical-stage DGAT-2 inhibitor to expand its MASH treatment pipeline.
This combination of rapid commercial uptake for Rezdiffra and external pipeline expansion with Pfizer highlights how Madrigal is trying to build a broader franchise in liver disease treatments.
We’ll now...